Is There an Oral Tirzepatide Pill? What Is Approved, and What the Online Drops Are

Quick answer

As of September 2026, there is no FDA-approved oral tirzepatide. Drugs@FDA lists exactly two tirzepatide applications, NDA 217806 (Zepbound) and NDA 215866 (Mounjaro), and every product under both is a solution for subcutaneous injection. The prescribing information for each describes "pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens", never a tablet. Products advertised online as oral tirzepatide, tirzepatide drops or tirzepatide troches are, where the listing says what they are, compounded preparations; FDA also warns that it "monitors the internet for fraudulent or unapproved drugs" in this class. Compounded medications are not FDA-approved as final products.

That is the short version. The rest of this page walks through what is approved and in what form, which oral GLP-1 tablets do exist, why a peptide like tirzepatide resists being swallowed, what the online drops actually are, and how to check any offer before you hand over a prescription or a card number.

What form of tirzepatide has FDA approved?

The cleanest way to answer "is there a tirzepatide pill" is to read the government record rather than a sales page. Drugs@FDA is the agency's database of approved drug applications, and it can be queried by active ingredient. A live query on September 22, 2026 for tirzepatide returned two applications, both sponsored by Eli Lilly and Co:

• NDA 217806, Zepbound. Every product row reads dosage form SOLUTION, route SUBCUTANEOUS, marketing status Prescription. The product rows are named Zepbound, Zepbound KwikPen and Zepbound (Autoinjector).
• NDA 215866, Mounjaro. Same pattern: SOLUTION, SUBCUTANEOUS, Prescription, across the rows named Mounjaro, Mounjaro KwikPen and Mounjaro (Autoinjector).

The labels agree. Section 3 of both the Zepbound and Mounjaro prescribing information opens with the word "Injection" and describes "Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens." Section 11 of the Zepbound label calls the product "ZEPBOUND (tirzepatide) injection, for subcutaneous use" and describes tirzepatide as "a GIP receptor and GLP-1 receptor agonist."

The two brands differ by indication, not by molecule. Zepbound is labeled for weight reduction in adults with obesity, or overweight with at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is labeled "as an adjunct to diet and exercise to improve glycemic control" in type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes. Neither label lists an oral dosage form. For the device itself, see what the Zepbound KwikPen is.

Which oral GLP-1 medicines are FDA-approved?

The search for a tirzepatide pill usually comes from a reasonable wish: a GLP-1 medicine without a needle. Such medicines exist. They are not tirzepatide, and each is approved for specific conditions. What follows is names and labeled indications only, with no comparison of how well they work, because that comparison belongs in a physician's office.

Foundayo (orforglipron) tablets. Drugs@FDA lists NDA 220934, Foundayo, dosage form TABLET, route ORAL, with an original approval dated April 1, 2026 and classified as a new molecular entity. The label, effective July 29, 2026, states that Foundayo "is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition." Its description section calls orforglipron "a GLP-1 receptor agonist" and prints a molecular weight of about 902 g/mol, against 4813.53 Da for tirzepatide on the Zepbound label. That difference in size is a large part of why one is a tablet and the other is not, and it is covered in the next section. The label's warnings and adverse reactions are summarized in what the Foundayo label says about orforglipron side effects.

Rybelsus (semaglutide) tablets. The Rybelsus label, effective January 30, 2026, covers both Rybelsus and Ozempic tablets and lists them "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and for cardiovascular risk reduction in adults with type 2 diabetes. That label does not list weight management as an indication.

Wegovy (semaglutide) tablets. Drugs@FDA lists NDA 218316, Wegovy, TABLET, ORAL, with an original approval dated December 22, 2025 and classified as a new dosage form. The combined Wegovy label, effective June 18, 2026, carries a separate paragraph for the tablets: they are indicated "to reduce the risk of major adverse CV events" in adults with established cardiovascular disease and obesity or overweight, and "to reduce excess body weight and maintain weight reduction long term" in adults with obesity or overweight with a weight-related condition.

So the honest answer to "tirzepatide pills" is that the pills on the market contain orforglipron or semaglutide. If you are new to the class, what a GLP-1 medication is explains the shared mechanism.

Why is a tirzepatide pill so hard to make?

Tirzepatide is a peptide, a chain of amino acids. The digestive system is built to break peptides apart, because that is what it does to the protein in food. A 2024 review in the International Journal of Molecular Sciences, indexed on PubMed Central, puts it plainly: peptide and protein drugs "due to their specific chemical structure are typically delivered parenterally, which ensures optimal bioavailability." The same review lists the obstacles to swallowing them, "their instability depending on digestive enzymes and pH changes in the gastrointestinal (GI) system on the one hand, but also their limited permeability across physiological barriers (mucus and epithelium) on the other hand."

The one approved oral peptide GLP-1, semaglutide, shows what it takes. The Rybelsus label explains that the tablets "are co-formulated with SNAC which facilitates the absorption of semaglutide after oral administration. The absorption of semaglutide predominantly occurs in the stomach." In other words, an absorption enhancer, a specific tablet design, and a regulatory review of exactly how much drug reaches the blood. Orforglipron is a much smaller molecule, and its approved form is a tablet. Tirzepatide has no FDA-reviewed oral formulation, and Drugs@FDA lists no oral product containing it.

Is a tirzepatide pill in development?

That is a question only the manufacturer can answer, and this page does not repeat secondhand reporting about pipelines or press releases. It states what the primary record shows. As of September 22, 2026, Drugs@FDA lists no oral tirzepatide product, and the oral GLP-1 tablet it lists from the same manufacturer is orforglipron (Foundayo). Drugs@FDA shows approved applications, not pending ones, so it cannot say what is under review. The verification date is printed on this page so the record can be rechecked.

What are the oral tirzepatide drops and troches sold online?

Type the phrase into a search engine and the results include sellers offering "oral tirzepatide drops", sublingual troches and dissolving tablets. Read the listing closely and the product is described as a compounded preparation: a pharmacy mixes tirzepatide into a liquid or a lozenge under a prescription. FDA's own compounding Q&A states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The agency's page on unapproved GLP-1 drugs, current as of September 1, 2026, repeats that "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed" and names tirzepatide specifically. Compounded medications are not FDA-approved as final products. FDA has not reviewed how much tirzepatide, if any, enters the bloodstream from under the tongue, and no human study answering that question was found among the sources read for this article. That evidence gap, the pharmacology behind it, and the questions to ask a seller are covered in depth in what is known about sublingual tirzepatide; the wider landscape of tablets, drops and patches is in oral and sublingual GLP-1 forms. The regulatory status of compounded tirzepatide injections is a separate topic, covered in is compounded tirzepatide safe.

Checking an oral tirzepatide offer

Whether you found tirzepatide online as drops, a troche or a tablet, the same four checks apply, and each one uses a source you can open yourself.

1. A prescription is required. Drugs@FDA marks every tirzepatide product as marketing status Prescription. FDA's list of telehealth red flags includes a company that "does not require a screening and prescription by a licensed doctor before providing medicine" and one that "does not have a licensed doctor available to answer questions after you receive your medication." An offer that skips the physician has already failed.
2. Find the pharmacy and look up its license. A legitimate seller will name the pharmacy that prepares the product. The National Association of Boards of Pharmacy maintains a directory of state boards, described on its site as the way to "connect with your board" by "selecting a state below." Use that directory to reach the board for the pharmacy's state and verify the license there. NABP's consumer site adds that verified pharmacies "are licensed by regulators in the jurisdiction in which they are located, as well as regulators in the patient's jurisdiction" and "accept only valid prescriptions."
3. Use FDA's BeSafeRx resources. BeSafeRx exists to help consumers "recognize the signs of safe online pharmacies and the warning signs of websites that appear to be pharmacies but may be unsafe," and it links a tool to "Locate a State-Licensed Online Pharmacy."
4. Read the label you receive. FDA's red-flag list includes a label with spelling errors, an incorrect pharmacy address, or a pharmacy name that you think might be fraudulent. How to read a prescription label walks through each line.

A seller that passes all four checks is still selling a product FDA has not reviewed. That is a fact to weigh with a physician, not a reason to skip the checks. For the parallel question about semaglutide, see is compounded semaglutide FDA approved, and for the pricing side of the search, is there a generic Zepbound.

Questions to bring to a physician

If the reason you searched for a tirzepatide pill is needle avoidance, that is a legitimate clinical conversation. Useful questions:

• Is an approved oral GLP-1 tablet appropriate for my diagnosis, given what each label is actually indicated for?
• If a compounded oral or sublingual tirzepatide is being suggested, what evidence supports absorption by that route, and who prepares it?
• What in my medical history matters for any GLP-1 medicine, including thyroid, pancreas and gallbladder history?
• How will we know whether a medicine is working, and what would prompt a change?

Prescribing decisions belong to a licensed physician who can see your history. Approval status was checked against Drugs@FDA on September 22, 2026 and can change; the database is public and worth rechecking before you act on any page, including this one. General questions about how telehealth prescribing works are answered in the help center.

This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved as final products. Medication is prescribed only if a licensed physician determines it is appropriate. Regulatory status was verified on September 22, 2026 and may change.